topotecan

Topotecan (NSC-609669) is a Topoisomerase I inhibitor,and is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases.

Topotecan hydrochloride (NSC609699) is an antineoplastic agent used to treat ovarian cancer.

Topotecan acetate is an inhibitor of topoisomerase.

Topotecan hydrochloride hydrate is an orally active Topoisomerase I inhibitor with anticancer properties capable of blocking the cell cycle in the G0 G1 and S phases and inducing apoptosis.

NU1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitors have been developed that potentiate the cytotoxicity of ionizing radiation and anticancer drugs. The biological effects of NU1085 [Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer). Cells were treated with increasing concentrations of TM or TP + - NU1085 (10 microM) for 72 h.

PV-1019 (NSC 744039) is a potent and selective inhibitor of Chk2 with an IC50 of 24 nM, effectively inhibiting Topotecan-induced Chk2 autophosphorylation and suppressing IR-induced apoptosis [1].

TX-2552 is an orally effective inhibitor of tyrosyl-DNA phosphodiesterase 1 (TDP1), with an IC50 value of 0.62 μM. It enhances the cleavage activity of topotecan in mouse bone marrow cells and amplifies the antitumor effects of topotecan in Krebs-2 ascites tumor-bearing mice.

Oliveroline is an alkaloid found in plants that demonstrates strong inhibition of Topo I and remarkable inhibition of Topo II, surpassing similar compounds such as topotecan and etoposide. The Topo I complexes it forms are more stable than those with Topo II, highlighting its potential as a promising candidate for further cancer treatment research.